Natco Pharma Q1 FY27 profit drops 57% to Rs 206.5 crore on weaker lenalidomide sales
AI Market Summary
Natco Pharma reported a sharp Q1 FY27 earnings miss: net profit fell 57% YoY and revenue dropped 44.7%, driven by weaker lenalidomide sales and a steep decline in international formulations. EBITDA contracted 67.4% with margins compressing to 25.3%, signaling operating leverage reversal. An interim dividend and approval to raise up to ₹2,000 crore via QIP add balance-sheet flexibility but do not offset near-term demand pressure.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT+0.99%
AI Insight · NCCOGOLD2USD/USDTAI Insight
▼ Bearish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Natco Pharma said its consolidated net profit fell 57% year on year to Rs 206.5 crore in Q1 FY27, hit by weaker sales of its generic cancer drug lenalidomide. Revenue from operations declined 44.7% to Rs 735.2 crore from Rs 1,328.9 crore a year earlier. The company’s board approved an interim dividend of Rs 1.50 per equity share.
